Real World Evidence Analyst
in health
The person who turns messy real-world health data into evidence that survives scrutiny from payers regulators and clinicians.
A Real World Evidence (RWE) Analyst turns health data generated outside controlled clinical trials into evidence that holds up under scrutiny. That data comes from electronic health records, disease registries, insurance and claims systems, connected devices, and the everyday flow of care. The job exists because products and treatments often behave differently in real practice than they did in a trial: populations are more varied, people miss doses, services differ between sites, and outcomes are shaped by system pressures as much as by the intervention itself. Someone has to measure what actually happens and say honestly what the data can and cannot prove.
The role sits across the regulated sector rather than in one corner of it. You will find RWE Analysts in pharma and biotech medical affairs and market access teams, in health economics and outcomes research (HEOR) consultancies such as the firms that advise on NICE submissions, in contract research organisations (CROs) delivering observational studies for sponsors, in medical device and diagnostics companies building post-market evidence, in NHS and academic analytics teams, and in digital-health scale-ups proving their product changes outcomes. The setting changes the data sources, the pace, and who is asking the question. The core accountability does not.
At heart this is an ownership role. An RWE Analyst owns the integrity of the evidence used to make decisions: what to build, where it works and where it does not, how value is demonstrated to a payer, and what change in care is genuinely justified. The job is to produce analyses that are interpretable, defensible, and useful, while being candid about uncertainty, bias, and the limits of the data.
How this role differs in health and life sciences
In most commercial analytics, evidence is about growth: conversion, churn, retention. A wrong call is usually reversible and the stakes stay inside the business. In health and life sciences the same analysis can inform a clinical decision, a NICE or payer reimbursement decision, a regulatory submission to the MHRA, and ultimately patient outcomes. The bar for rigour and traceability is higher and the tolerance for ambiguity is lower.
The data problem is harder too. You work with sensitive personal data under UK GDPR and the Data Protection Act, incomplete records, coding practices that shift over time, and real-world confounding that can make a naive before-and-after comparison dangerously misleading. The work leans less on shipping dashboards quickly and more on careful calls under constraint: information governance approvals, the discipline of Good Pharmacoepidemiology Practice, study registration and transparency expectations, and the operational reality of NHS and care settings where data was never collected for research in the first place.
The audience is different as well. An RWE Analyst has to communicate to people who will challenge the evidence from several angles at once: clinical leaders, data governance teams, commercial and market-access colleagues, HTA bodies such as NICE, and external evaluators, each with their own definition of good enough. Holding a methodological line under that pressure is part of the job.
Core responsibilities in health and life sciences
Day to day, an RWE Analyst shapes questions into studies that can actually be answered with available data, then delivers results solid enough to inform a real decision. The work blends study design, hands-on analysis, and a lot of judgement under time pressure. Core responsibilities usually include:
- Translate a business clinical or market-access question into a feasible study: define the population, the comparison, the endpoints, and what success means in a real-world setting rather than an idealised one.
- Assess data sources for fitness: understand provenance, coverage, missingness, and coding so the dataset can support the claim being made.
- Design observational studies that account for confounding and selection effects, and choose methods (propensity scoring, time-to-event analysis, sensitivity analyses) that match the question rather than the convenience.
- Build and validate cohorts: document how they were defined, how variables were derived, what was excluded, and why, so the work stays reproducible.
- Run the analysis in code (commonly R, SAS, SQL, or Python) and keep a clear audit trail from raw data through every transformation to the final result.
- Work inside information governance and privacy controls without quietly weakening the research question.
- Interpret and write up findings so they withstand challenge: state assumptions, limitations, and what would be needed to conclude more.
- Hold the line on what the evidence supports when commercial or delivery pressure pushes toward overclaiming.
Much of the role is trade-offs. You might have a clinically meaningful outcome that is poorly recorded, or a dataset that is accessible but too biased for the claim. The analyst decides when to redesign the study, when to narrow the claim, when to seek another data source, and when to say plainly that the data cannot answer the question. Being able to say that, especially under pressure, is part of what makes the evidence function worth having.
Skills and competencies for health and life sciences
| Core skill | What it looks like in this sector | Why it matters |
|---|---|---|
| Evidence ownership | Taking responsibility for whether a conclusion is safe to act on not just whether the analysis ran | Prevents overclaiming and reduces clinical reputational and reimbursement risk downstream |
| Study design judgement | Choosing designs and methods that fit real-world constraints such as confounding and variable data quality | Produces evidence that reflects practice and avoids false certainty from inappropriate methods |
| Causal and statistical method | Comfort with confounding adjustment time-to-event analysis and sensitivity testing | Lets you defend findings to statisticians payers and HTA reviewers who will probe the assumptions |
| Health-data fluency | Reading EHR registry and claims data including coding (ICD SNOMED OPCS) and its quirks | Stops avoidable errors from misread fields and makes variables reflect real care |
| Technical analysis | Working in R SAS SQL or Python with reproducible documented code | Supports re-analysis audit and scaling beyond one-off scripts |
| Governance fluency | Operating within privacy security and data-access controls under UK GDPR | Keeps evidence generation moving while respecting patient trust and legal obligations |
| Bias awareness and humility | Treating confounding missingness and selection as first-class problems | Protects decision-makers from clean-looking outputs that are not actually causal or generalisable |
| Communication for scrutiny | Writing and presenting in a way that survives challenge from clinical commercial and external reviewers | Enables adoption by cautious stakeholders and supports NICE or regulatory evaluation where needed |
Salary ranges in UK health and life sciences
Pay is driven less by the job title and more by the scope of accountability: whether you own a single study or an evidence programme, how exposed the work is to external scrutiny (payer submissions, regulatory evidence, HTA review), how sensitive and complex the data environment is, and how much you are expected to influence stakeholders who may dislike an uncomfortable finding. Setting matters too. HEOR consultancies, large pharma, and CROs tend to pay more than NHS or academic analytics teams, where Agenda for Change bands often apply and clusters sit lower. Location still moves the number, but the biggest step changes come from specialism (epidemiology, biostatistics, health economics), autonomy, and the cost of being wrong.
| Experience level | Estimated annual salary range | What drives compensation |
|---|---|---|
| Junior | London & South East: £33,000 to £43,000. Rest of UK: £30,000 to £40,000 | Supervised analysis limited ownership of methodological decisions lower stakeholder exposure |
| Mid-level | London & South East: £43,000 to £58,000. Rest of UK: £40,000 to £53,000 | Owning end-to-end studies translating questions into defensible designs handling data quality trade-offs |
| Senior | London & South East: £58,000 to £78,000. Rest of UK: £52,000 to £72,000 | Leading complex programmes higher scrutiny work payer and regulatory exposure mentoring |
| Lead | London & South East: £78,000 to £102,000. Rest of UK: £70,000 to £95,000 | Evidence strategy for a product area governance leadership prioritisation owning standards and review |
| Head / Director | London & South East: £100,000 to £150,000. Rest of UK: £92,000 to £138,000 | Function-wide accountability external credibility budget and vendor ownership portfolio and risk decisions |
Sources: Glassdoor UK as of June 2026 (Real World Evidence Consultant average around £42,000 with a typical range of £34,000 to £52,000 and top earners near £62,000; consultancy and vendor submissions such as OPEN Health, IQVIA, and Oracle clustering £43,000 to £58,000; Health Economics and Outcomes Research Analyst spanning roughly £27,000 to £55,000), senior real-world data and epidemiology postings on Indeed and SimplyHired (£57,000 to £87,000 for senior analytic roles, with experienced real-world programming and data-science roles in London reaching £81,000 to £145,000), Reed data-analyst benchmarks (£40,000 to £50,000 in London), and NHS Agenda for Change banding for public-sector and academic analytics roles. The exact title is niche, so these triangulate adjacent roles (RWE consultant, HEOR analyst, epidemiology data analyst, real-world data scientist). Treat these as a guide. Real offers move with employer setting and specialism.
Beyond base salary, total compensation varies by employer type. HEOR consultancies and evidence agencies more often add performance bonuses or profit share; pharma and venture-backed digital-health firms are more likely to include equity, with wide variation by stage. On-call is rare for pure RWE work, but it can appear where evidence and analytics sit inside a live clinical service or safety-monitoring context, usually tied to incident response rather than routine analysis. Total compensation shifts most with seniority, stakeholder exposure, and how close the evidence sits to externally scrutinised decisions.
Career pathways
Most RWE Analysts enter through adjacent routes: epidemiology or public-health analytics, outcomes research or HEOR roles, NHS or academic analytical teams, life-sciences consulting, biostatistics, or data roles where they have wrestled with messy real-world healthcare data. Some come from academic research. Progression tends to accelerate once you can show you have owned decisions, not just produced outputs.
As responsibility grows, the work moves from answer this question to choose the right question, define the claim, and defend the evidence. Mid-career expansion usually comes from owning studies end to end, including stakeholder alignment and honest limitations management. Senior progression is earned by handling ambiguity and scrutiny: leading sensitive work, building governance-friendly processes, and mentoring so evidence quality scales beyond you. Lead and Head or Director pathways are defined by portfolio ownership: setting evidence strategy, deciding what not to do, and protecting credibility when commercial pressure rises.
FAQ
Will I be expected to make causal claims from observational data? You may be asked for proof, but strong teams expect you to frame what the data can and cannot support. Interviewers look for how you handle confounding, bias, and alternative explanations, and how you adjust a claim to fit the evidence. Your credibility rises when you can say clearly here is what we can conclude and here is what would be needed to conclude more.
What does good look like in the first 90 days? Usually mapping stakeholders, clarifying the real evidence needs, and producing one or two analyses that are both useful and methodologically transparent. Teams value an analyst who improves decision quality, not someone who ships the most charts. Expect to spend real time understanding data provenance, definitions, missingness, and governance constraints before moving faster.
Do RWE Analysts get on-call, and how should I ask about it? Many roles have no formal on-call, especially when the evidence supports product or market-access strategy rather than live clinical operations. If the role sits near a monitored service or safety process there may be rota expectations around data quality events or urgent reporting. Ask directly what out of hours looks like in practice, what triggers escalation, and whether there is an allowance or time off in lieu.
Find your next role
Ready to put your evidence and analytics skills to work across pharma, HEOR consultancies, CROs, medical devices, diagnostics, the NHS, and digital health? Search Real World Evidence Analyst roles on Meeveem.